Physician profile
David K Young
NPI 1548230329
$35,941.47
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $8,184 · 2021: $11K · 2022: $1,886 · 2023: $53.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,551.11 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $660.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $624.44 | 2019-2021 | |
| Grifols USA, LLC | $603.35 | 2019-2021 | |
| Mylan Specialty L.P. | $206.49 | 2019-2021 | |
| Insmed, INC. | $177.85 | 2019 | |
| Genzyme Corporation | $155.12 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $109.08 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $108.20 | 2019-2021 | |
| Genentech USA, INC. | $105.52 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $71.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.80 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.81 | 2020 | |
| United Therapeutics Corporation | $50.84 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $45.97 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $45.62 | 2019 | |
| Mallinckrodt Hospital Products INC. | $33.82 | 2020-2021 | |
| Electromed, INC. | $26.82 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $25.11 | 2021 | |
| Melinta Therapeutics, LLC | $21.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.84 | 2020 | |
| Eisai INC. | $19.42 | 2021 | |
| Advanced Respiratory, INC | $18.76 | 2020 | |
| Circassia INC. | $18.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.63 | 2021 | |
| Phadia US INC. | $16.55 | 2019 | |
| La Jolla Pharmaceutical Company | $15.23 | 2020 | |
| Harmony Biosciences LLC | $14.91 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.79 | 2019 | |
| Shire North American Group INC | $13.62 | 2019 | |
| Covidien LP | $13.38 | 2020 | |
| Pulmonx Corporation | $11.68 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.